Galectin Therapeutics (GALT) Capital Expenditures (2012)
Galectin Therapeutics (GALT) recorded Capital Expenditures of $3,000 in Q4 2012.
Powered by 
Analysis
Galectin Therapeutics (GALT) Capital Expenditures (2012) Analysis & Trends
For FY2012, Galectin Therapeutics reported Capital Expenditures of $5,000, unchanged from FY2011.
- Across earlier years, Capital Expenditures came in at $5,000 in FY2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | -321.00 Mn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | -763.00 Mn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 112.20 Mn |
| 10 | Galectin Therapeutics | 257.29 Mn | 257.29 Mn | - | - |
API Access
Galectin Therapeutics Capital Expenditures API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=capital-expenditures&ticker=GALT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "capital-expenditures", "ticker": "GALT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=capital-expenditures&ticker=GALT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();